Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market
Executive Summary
At the ASCO 2016 meeting, researchers compared results for kidney cancer trials; Bristol's Opdivo gets kudos for tolerability.
You may also be interested in...
Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.
Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting
During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.
ASCO Round-Up: Array, Kite, Exelixis, Pfizer/Merck KGAA, Mylan, Novartis
The annual American Society of Clinical Oncology (ASCO) conference has been ongoing the last several days in Chicago, giving companies the chance to showcase their work in a range of cancers. Here's a look at some of the highlights.